International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf ·...
Transcript of International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf ·...
![Page 1: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/1.jpg)
![Page 2: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/2.jpg)
![Page 3: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/3.jpg)
International PTCL StudyInternational PTCL StudyStudy Sites Number Cases %Study Sites Number Cases %
North North AmericaAmerica
6 sites6 sites 333333 25.225.2
EuropeEurope 7 sites7 sites 452452 34.234.2
Far EastFar East 8 sites8 sites 535535 40.640.6
Presented by D.D. Weisenburger at the Meeting Presented by D.D. Weisenburger at the Meeting ““ItIt’’s time to takes time to takecare of Tcare of T--cell lymphomascell lymphomas””, held in Bologna, October 22, held in Bologna, October 22--24, 200624, 2006
![Page 4: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/4.jpg)
Median ageMedian age
Stage IVStage IV
IPI 3IPI 3--55
PresentationPresentation•• NodalNodal
•• ExtraExtra--nodalnodal
•• Nodal + extraNodal + extra--nodalnodal
55--year RFSyear RFS
55--year OSyear OS
PTCL/NOS PTCL/NOS -- Clinical FeaturesClinical Features
~ ~ 60 years60 years
60%60%
60%60%
22%22%16%16%62%62%26%26%20%20%
![Page 5: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/5.jpg)
DiagnosisDiagnosis CENSORCENSOR FAILFAIL TOTALTOTAL MEDIANMEDIAN
Angioimmunoblastic TAngioimmunoblastic T--cell lymphomacell lymphoma 8787 154154 241241 2.262.26
Peripheral TPeripheral T--cell lymphomacell lymphoma--NOSNOS 112112 218218 330330 2.012.01
Test: p=0.89Test: p=0.89
Overall SurvivalOverall SurvivalPeripheral TPeripheral T--cell Lymphomacell Lymphoma--NOS, andNOS, and
Disease subDisease sub--group: Angioimmunoblastic Tgroup: Angioimmunoblastic T--cell lymphoma cell lymphoma
Prop
orti
onPr
opor
tion
0.00.0
0.10.1
0.20.2
0.30.3
0.40.4
0.50.5
0.60.6
0.70.7
0.80.8
0.90.9
1.01.0
TimeTime
00 11 22 33 44 55 66 77 88 99 1010 1111 1212 1313 1414 1515 1616 1717 1818 1919
International peripheralInternational peripheralTT--cell lymphoma projectcell lymphoma project
![Page 6: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/6.jpg)
Morphologic spectrumMorphologic spectrum
![Page 7: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/7.jpg)
T zone typeT zone type
PTCLnos: peculiar morphologic patternsPTCLnos: peculiar morphologic patterns
GCGC
![Page 8: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/8.jpg)
Low magnification: Hodgkin like patternLow magnification: Hodgkin like pattern
LymphoLympho--epithelioid cell type (Lennertepithelioid cell type (Lennert’’s lymphoma)s lymphoma)
![Page 9: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/9.jpg)
No marked pleomorphism of tumoural cellsNo marked pleomorphism of tumoural cells
![Page 10: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/10.jpg)
![Page 11: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/11.jpg)
Macon WR et al. Am J Surg Pathol 1995, 19:297-303 Rudiger T et al. AM J Surg Pathol 2000, 24:117-22de Leval L et al. Am J Surg Pathol 2001, 25:395-400Jiang L et al. Am J Clin Pathol 2005, 123:448-55Ikonomou IM et al. Virchows Archiv 2006, 449:78-87Streubel B et al. Leukemia 2006, 20:313-18Bacon CM et al. Br J Haematol 2008, 143:439-50Qubaja M et al. Hum Pathol 2009, 40:264-69Huang Y et al. Am J Surg Pathol 2009, 33:682-90Ortiz-Muchotrigo N et al. Histopathol 2009, 54:901-3 Le Tourneau A et al. Histopathol 2010, 56:548-51.
![Page 12: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/12.jpg)
CD3CD3
![Page 13: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/13.jpg)
CD4CD4
CD8CD8
![Page 14: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/14.jpg)
CD10CD10 CXCL13CXCL13
PD1PD1
![Page 15: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/15.jpg)
CD21CD21
![Page 16: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/16.jpg)
![Page 17: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/17.jpg)
![Page 18: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/18.jpg)
DRDR-- PTCL/NOSPTCL/NOSDRDR++
Supervised analysisSupervised analysisgenes=185genes=185
Supervised analysisSupervised analysisgenes=70 genes=70
CD4CD4 CD8CD8 PTCL/NOSPTCL/NOS
Most PTCL/NOS are related to activated Most PTCL/NOS are related to activated central memorycentral memoryTT--cells; a small minority shows cytotoxic profile. cells; a small minority shows cytotoxic profile.
![Page 19: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/19.jpg)
![Page 20: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/20.jpg)
de Leval L. et al. Blood 2007; 109:4952-63.
![Page 21: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/21.jpg)
Prof. Dr. Dr. h.c. Karl Lennert Prof. Dr. Dr. h.c. Karl Lennert -- Kiel, 2009Kiel, 2009
![Page 22: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/22.jpg)
Agostinelli C, Hartmann S, Klapper W, Agostinelli C, Hartmann S, Klapper W, KorkolopolouKorkolopolou P, P, RighiRighi S, Marafioti T, S, Marafioti T, Piccaluga PP, Piccaluga PP, PatsourisPatsouris E, E, HansmannHansmann MM--L, Lennert K and Pileri SA. L, Lennert K and Pileri SA.
Peripheral TPeripheral T--cell lymphomas with follicular Tcell lymphomas with follicular T--helper phenotype: a new basket helper phenotype: a new basket or a distinct entity? Revising Karl Lennertor a distinct entity? Revising Karl Lennert’’s personal archive. s personal archive.
Histopathology, 2011, 59:1173Histopathology, 2011, 59:1173--82. 82.
![Page 23: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/23.jpg)
A road to a new category of TFHA road to a new category of TFH--PTCLs?PTCLs?
![Page 24: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/24.jpg)
Training setTraining set Test setTest set CD4CD4--CD8CD8--DR+DR+
00
PTCL/NOSPTCL/NOS
Normal lymphocytesNormal lymphocytes
Genes differentially expressed in PTCL/NOS Genes differentially expressed in PTCL/NOS and normal Tand normal T--cells (training set + test set)cells (training set + test set)
Supervised analysis 155 genes: 91 downSupervised analysis 155 genes: 91 down--regulated and 64 upregulated and 64 up--regulatedregulated
![Page 25: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/25.jpg)
Cellular programs deCellular programs de--regulated in PTCL/NOSregulated in PTCL/NOS
AdhesionAdhesionApoptosisApoptosis
MatrixMatrix
ProliferationProliferationSignal transductionSignal transduction
CytoskeletonCytoskeleton TranscriptionTranscriptionPER1PER1CBX4CBX4CHD2CHD2COPEBCOPEBCREMCREMEPC1EPC1JMJD1CJMJD1CMAFMAFNR4A2NR4A2NR4A3NR4A3SERTAD1SERTAD1ZBTB10ZBTB10ZBTB24ZBTB24ZNF198ZNF198ZNF331ZNF331BCL10BCL10
GJA1GJA1TNSTNSVCAM1VCAM1LIFRLIFR
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
CD69CD69DUSP2DUSP2DUSP8DUSP8GADD45AGADD45AGADD45BGADD45BING3ING3JUNDJUNDMOAP1MOAP1PPP1R15APPP1R15A
FN1FN1COL12A1COL12A1COL1A2COL1A2COL3A1COL3A1COL4A1COL4A1COL4A2COL4A2FBN1FBN1LAMB1LAMB1SPARCSPARCCDH11CDH11
AXUD1AXUD1FOXP1FOXP1RHOBTB3RHOBTB3CAV2CAV2PLEKHC1PLEKHC1BTG1BTG1CLK1CLK1HECAHECAJUNJUNRGC32RGC32TOB1TOB1
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
CALD1CALD1STK17BSTK17BMKNK2MKNK2HIPK1HIPK1PTP4A1PTP4A1PDE4DPDE4DMAP3K8MAP3K8ITPKBITPKBSEPT10SEPT10TJP1TJP1IRS2IRS2
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
TPM1TPM1Dlc2Dlc2MGAT4AMGAT4AMYLIPMYLIPNFIBNFIBWASPIPWASPIP
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
PTCL/NOSPTCL/NOS CD4CD4--CD8CD8--DR+DR+
![Page 26: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/26.jpg)
CaldesmonCaldesmon ((⇑⇑))
LIFR (LIFR (⇑⇑))
BCL10 (BCL10 (⇓⇓))
pp--PDGFRPDGFRαα
p27 (p27 (⇑⇑))
IGFBP7 (IGFBP7 (⇑⇑))
PDGFRPDGFRαα ((⇑⇑))
CYR61 (CYR61 (⇑⇑))
![Page 27: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/27.jpg)
Piccaluga PP, et al The Lancet Oncology, 2005; 6: 440Piccaluga PP, et al The Lancet Oncology, 2005; 6: 440
Expression of plateletExpression of platelet--derived growth factor derived growth factor receptor in PTCL/NOSreceptor in PTCL/NOS
Training setTraining set Test setTest set CD4CD4--CD8CD8--DR+DR+
PDGFRaPDGFRa
PDGFRAPDGFRA
PTCL/NOSPTCL/NOS
TK TK inhibitorsinhibitors
![Page 28: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/28.jpg)
Imatinib reduces cell viability, by inducing cell cycle Imatinib reduces cell viability, by inducing cell cycle arrest and apoptosis in PTCL/NOS primary cellsarrest and apoptosis in PTCL/NOS primary cells
0
20
40
60
80
100
120
0 6 12 18 24 30 36 42 48 54 60 66 72
Control Sugen 0,3 mM Sugen 1 mM
0
20
40
60
80
100
120
0 6 12 18 24 30 36 42 48 54 60 66 72
Control Sugen 0,3 mM Sugen 1 mM
AnnexinAnnexin V: t48hV: t48h
MediumMedium
Medium +Medium +Imatinib 1 Imatinib 1 mMmM
BrdUrdBrdUrd proliferationproliferation assayassay; 48 h; 48 h
00101020203030404050506060707080809090
100100
ControlControl ImatinibImatinib
G1G1SSG2G2--MM
![Page 29: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/29.jpg)
Imatinib is more effective than daunorubicin Imatinib is more effective than daunorubicin and gemcitabine against and gemcitabine against PTCLnosPTCLnos primary primary
cellscells
0
20
40
60
80
100
120
0 8 16 24 32 40 48 56 64 72
Control Dauno 5mM Imatinib 1 mM
0
20
40
60
80
100
120
0 24 48 72
Control Dauno 5 mM Imatinib 1 mM
020406080
100120
0 24 48 72
ControlGemcitabine 0,5 mMGemcitabine 0,5 mM + Imatinib 1 mMImatinib 1 mM
0
20
40
60
80
100
120
0 24 48 72
Control Sugen 0,3 mMSugen 1 mM Gemcitabine 0,5 mM
![Page 30: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/30.jpg)
![Page 31: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/31.jpg)
HDACiHDACi
CD69CD69DUSP2DUSP2DUSP8DUSP8GADD45AGADD45AGADD45BGADD45BING3ING3JUNDJUNDMOAP1MOAP1PPP1R15APPP1R15A
Histone deacetylase Histone deacetylase inhibitorsinhibitors
![Page 32: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/32.jpg)
HDACi is dramatically effective against HDACi is dramatically effective against PTCLnosPTCLnosprimary cellsprimary cells
0102030405060708090
100
0 24 48
Control ITF 0.5 mM ITF 1 mM ITF 5 mM
BrdUrdBrdUrd proliferationproliferation assayassay; 48 h; 48 h
AnnexinAnnexin V V assayassay; 48 h; 48 h
00
5050
100100
ControlControl +HDACi+HDACi
G1G1SS
![Page 33: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/33.jpg)
![Page 34: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/34.jpg)
Peripheral T-cell lymphomas(leukaemic and extranodal)
Alma MaterStudiorum
1088 d.C.
![Page 35: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/35.jpg)
![Page 36: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/36.jpg)
TT--cell prolymphocytic leukemiacell prolymphocytic leukemia
2% of cases of mature lymphocytic leukaemia2% of cases of mature lymphocytic leukaemia
Clinical featuresClinical features
Median ageMedian age (range) (range) 65 years65 years (30 (30 -- 94)94)M : F ratioM : F ratio 1. 31. 3HepatosplenomegalyHepatosplenomegaly 79%79%LymphadenopathyLymphadenopathy 46%46%Skin lesionsSkin lesions 23%23%EffusionsEffusions 12%12%WBC x 10WBC x 1099/L/L > 100> 100Hb < 10 g/dlHb < 10 g/dl 25%25%Platelets < 100 x 10Platelets < 100 x 1099/L/L 44%44%
![Page 37: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/37.jpg)
Morphology: PMorphology: Prolymphocytic rolymphocytic 75%75%
Peripheral bloodPeripheral blood
Cytoplasmic protrusions or blebsCytoplasmic protrusions or blebs
![Page 38: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/38.jpg)
Small cell Small cell 20%20%
Lymph nodeLymph node
![Page 39: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/39.jpg)
Cerebriform 5Cerebriform 5%%
![Page 40: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/40.jpg)
TT--PLL hairy cell leukaemiaPLL hairy cell leukaemia--likelike CD3CD3
Peripheral bloodPeripheral blood
![Page 41: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/41.jpg)
ImmunophenotypeImmunophenotype
AntigenAntigen % of cases% of cases++
CD3CD3 8484
CD4+/CD8CD4+/CD8-- 6060
CD4+/CD8CD4+/CD8++ 2525
CD4CD4--/CD8/CD8++ 1010
TCL1TCL1 7171
All: All: CD52CD52++, CD2, CD2++, CD5, CD5++, CD7, CD7++, TdT, TdT--, CD1a, CD1a--, NK markers, NK markers--. .
Cytotoxic markes: negative.Cytotoxic markes: negative.
CD3CD3+ + BM infiltrateBM infiltrate
![Page 42: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/42.jpg)
Complex karyotypeComplex karyotype
80%80%7070--80%80%
TCL1TCL1
ATMATM
p53 delp53 del
![Page 43: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/43.jpg)
Prognosis and predictive factorsPrognosis and predictive factors
•• Median survival less than 1 yearMedian survival less than 1 year
•• Cases with a more chronic course: accelerated Cases with a more chronic course: accelerated phase after 2phase after 2--3 years3 years
•• AlemtuzumabAlemtuzumab
•• Autologous or allogeneic stem cell transplantationAutologous or allogeneic stem cell transplantation
•• High expression of TCLHigh expression of TCL--1 and AKT: poor outcome1 and AKT: poor outcome
![Page 44: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/44.jpg)
TT--cell LGL leukaemiacell LGL leukaemia(2(2--3% of mature lymphocytic leukaemias)3% of mature lymphocytic leukaemias)
Definition: Definition: increased number of circulating LGLs (2increased number of circulating LGLs (2--20x1020x1099/L) lasting at least 6 /L) lasting at least 6 months and without a clearly identified cause, often arising in months and without a clearly identified cause, often arising in a setting a setting of immune stimulation of immune stimulation
Clinical features:Clinical features:-- No clearNo clear--cut sex and age prevalence (45cut sex and age prevalence (45--75 years)75 years)-- involvement of the peripheral blood, bone marrow, liver and spleinvolvement of the peripheral blood, bone marrow, liver and spleen en -- severe neutropeniasevere neutropenia with/without anaemiawith/without anaemia-- possible recurrent bacterial infectionspossible recurrent bacterial infections-- moderate splenomegalymoderate splenomegaly-- frequent association with rheumatoid arthritis, autofrequent association with rheumatoid arthritis, auto--antibodiesantibodies-- circulating immune complexes and hypergammaglobulinemiacirculating immune complexes and hypergammaglobulinemia-- TT--LGL clonal expansions following allogeneic BMT LGL clonal expansions following allogeneic BMT -- typically typically indolentindolent clinical courseclinical course
![Page 45: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/45.jpg)
Azurophilic granulesAzurophilic granulese.me.m.: parallel tubular arrays; .: parallel tubular arrays;
cytotoxic proteins.cytotoxic proteins.
DisDis--maturation of the haematopoietic series!maturation of the haematopoietic series!MildMild fibrosisfibrosis
50%: hypercellular50%: hypercellular50%: 50%: normonormo//hypohypo--
cellularcellular
![Page 46: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/46.jpg)
SpleenSpleen
![Page 47: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/47.jpg)
CD3CD3
CD57CD57
Phenotype:Phenotype:
TIATIA--11++, Granzyme B, Granzyme B++, Granzyme M, Granzyme M++, , perforinperforin++, CD57, CD57+v+v
High expression of High expression of FAS and FASFAS and FAS--LL
80%: CD380%: CD3++, , TCRTCRαα//ββ++, CD4, CD4--, CD8, CD8++
variants: CD3variants: CD3++, , TCRTCRαα//ββ++, CD4, CD4++, CD8, CD8--
CD3CD3++, , TCRTCRαα//ββ++, CD4, CD4++, CD8, CD8++
CD3CD3++, , TCRTCRγγ//δδ++, CD4, CD4vv, CD8, CD8vv
CD5 and CD7 expression: weak or CD5 and CD7 expression: weak or absentabsent
Genotype:Genotype:
TCR TCR γγ (+(+ββ) clonal rearrangement) clonal rearrangement
BM biopsy misleading without IHCBM biopsy misleading without IHC
![Page 48: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/48.jpg)
CD4CD4
CD8CD8
Reactive nodulesReactive noduleswith mixedwith mixed
composition (3+,composition (3+,4+>8+, CD20+)4+>8+, CD20+)
CD20CD20CD4CD4
![Page 49: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/49.jpg)
Chronic NK-cell LPD
• Morphologically LGL (blood and BM involvement)
• Phenotypically abnormal NK-cells (CD3εε+, CD16+, CD56+w, cytotoxic markers+, CD2-, CD7-, CD57-, CD5+, CD8+, EBV-)
• Blood LGL count ≥ 2x109/L
• Without obvious cause for the elevation
• Persists for > 6 months
• Associated with solid and haematological tumours, vasculitis, splenectomy, neuropathy and autoimmune disorders
• No worsening of the lympho-proliferation or clinical condition
• Exceptional transformation to an aggressive NK-cell disorder
![Page 50: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/50.jpg)
Granzyme BGranzyme B
![Page 51: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/51.jpg)
Phenotype & genotypePhenotype & genotype
CD2CD2++
CD3CD3--
CD3CD3εε++
CD56CD56++
CD16CD16+/+/--
CD57 usuallyCD57 usually--
cytotoxic moleculescytotoxic molecules++ (TIA(TIA--1; GB; perforin)1; GB; perforin)
TCR genes: germ line configurationTCR genes: germ line configuration
EBVEBV--
![Page 52: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/52.jpg)
Neither TCR rearrangement nor Neither TCR rearrangement nor karyotype abnormalities, but hints of karyotype abnormalities, but hints of
clonality!clonality!
•• XX--chromosome inactivationchromosome inactivation–– HUMARA HUMARA
•• ImmunophenotypingImmunophenotyping–– Unique profile of markersUnique profile of markers–– Restricted KIR expression patternRestricted KIR expression pattern
![Page 53: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/53.jpg)
KIR (KIR (kkiller cell iller cell IIgg--like like rreceptors)eceptors)•• Located on Located on 19p13.419p13.4•• Polymorphic in the Polymorphic in the KIRKIR genes present and genes present and
in the allele representedin the allele represented•• May have 2 or 3 IgMay have 2 or 3 Ig--like domain (2D,3D).like domain (2D,3D).•• May have a May have a long or short cytoplasmic taillong or short cytoplasmic tail (L (L
or S forms)or S forms)•• Long forms can transduce signals but short Long forms can transduce signals but short
forms need to associate with adaptors for forms need to associate with adaptors for signal transduction eg. DAP12signal transduction eg. DAP12
•• Can be activating or inhibitoryCan be activating or inhibitory but normal but normal NK cells always have one or more inhibitory NK cells always have one or more inhibitory KIRsKIRs
![Page 54: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/54.jpg)
Aggressive NKAggressive NK--cell leukaemia (EBVcell leukaemia (EBV++))
Clinical featuresClinical features rare (higher prevalence among rare (higher prevalence among AsiansAsians))young to middleyoung to middle--aged adults aged adults (mean age: 42 yrs)(mean age: 42 yrs)no sex predilectionno sex predilectionat onset: leukaemic blood picture, fever, Bat onset: leukaemic blood picture, fever, B--symptoms symptoms hepatosplenomegaly: commonhepatosplenomegaly: commonlymphadenopathy: occasionallymphadenopathy: occasionalskin lesions: uncommonskin lesions: uncommonelevated serum soluble elevated serum soluble FASFAS--LL levelslevels
ComplicationsComplications coagulopathycoagulopathyhaemophagocytic syndromehaemophagocytic syndromemultimulti--organ failureorgan failure
Clinical courseClinical course more often more often fulminantfulminant (mean survival: 2 months)(mean survival: 2 months)
![Page 55: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/55.jpg)
MarrowMarrow
![Page 56: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/56.jpg)
SpleenSpleen
![Page 57: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/57.jpg)
TestisTestis
![Page 58: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/58.jpg)
Phenotype & genotypePhenotype & genotype
CD2CD2++
CD3CD3--
CD3CD3εε++
CD56CD56++
CD16CD16+/+/--
CD57 usuallyCD57 usually--
cytotoxic moleculescytotoxic molecules++ (TIA(TIA--1; GB; perforin)1; GB; perforin)
TCR genes: germ line configurationTCR genes: germ line configurationdel(6)(q21;q25)del(6)(q21;q25)EBVEBV++
![Page 59: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/59.jpg)
CD3CD3εε
CD56CD56
![Page 60: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/60.jpg)
Adult TAdult T--cell lymphoma/leukaemiacell lymphoma/leukaemia
-- Discovered by Takatsuki et al. (1976)Discovered by Takatsuki et al. (1976)-- EndemicEndemic in: Southern Japan, Caribbean basin, and in: Southern Japan, Caribbean basin, and
Central AfricaCentral Africa-- The disease is The disease is linked to the prevalence oflinked to the prevalence of HTLVHTLV--1 1 in in
the populationthe population-- Incidence: 2.5% among HTLVIncidence: 2.5% among HTLV--1 carriers1 carriers-- Exposure to the virus in the early life (breast milk, Exposure to the virus in the early life (breast milk,
blood and blood products)blood and blood products)-- Long latencyLong latency-- Adults Adults (20 (20 -- 80 yrs80 yrs--old) old) with M/F = 1.5/1with M/F = 1.5/1-- HTLVHTLV--1 not sufficient to result in neoplastic 1 not sufficient to result in neoplastic
transformationtransformation
![Page 61: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/61.jpg)
Clinical variants:Clinical variants:
acuteacute: leukaemic phase, lymphadenopathy, hepatosplenomegaly, : leukaemic phase, lymphadenopathy, hepatosplenomegaly, skin rash, hypercalcaemia (lytic bone lesions) and associated Tskin rash, hypercalcaemia (lytic bone lesions) and associated T--cell immunodeficiencycell immunodeficiencylymphomatouslymphomatous: prominent lymphadenopathy without PB : prominent lymphadenopathy without PB involvement, cutaneous lesions common, hypercalcaemia less ofteninvolvement, cutaneous lesions common, hypercalcaemia less oftenseenseenchronicchronic: exfoliative skin rush, mild leukaemic component, : exfoliative skin rush, mild leukaemic component, hypercalcaemia absenthypercalcaemia absentsmoulderingsmouldering: >5% circulating neoplastic cells, frequent skin or : >5% circulating neoplastic cells, frequent skin or pulmonary lesionspulmonary lesions
Progression to an acute variant in 25% of chronic or smoulderingProgression to an acute variant in 25% of chronic or smoulderingcasescases
Adult TAdult T--cell lymphoma/leukaemiacell lymphoma/leukaemia
![Page 62: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/62.jpg)
![Page 63: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/63.jpg)
Overall survival of ATLL according to clinical subtypesOverall survival of ATLL according to clinical subtypes
Nagasaki Nagasaki UnvUnv..LeukLeuk Res 1993Res 1993
ShimoyamaShimoyama et alet alBrit J Brit J HaematolHaematol19911991
![Page 64: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/64.jpg)
Diversity of leukaemic cell morphology in ATLLDiversity of leukaemic cell morphology in ATLL
CytomorphologicalCytomorphological AcuteAcute ChronicChronicType (% lymph)Type (% lymph) (n=36) (n=36) (n=14) (n=14) p Valuep Value
PrototypePrototype 49%49% 29%29% 0.0150.015CLLCLL--likelike 17%17% 52%52% <0.0001<0.0001UnusualUnusual 20%20% 3%3% <0.0001<0.0001IntermediateIntermediate 8%8% 10%10% NSNS
AcuteAcute Acute crisisAcute crisis
AcuteAcute
AcuteAcuteChronicChronic
SmolderingSmolderingx1000x1000
x1000x1000
x1000x1000
x1000x1000
x1000x1000
x400x400
![Page 65: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/65.jpg)
CD2/3/5CD2/3/5++, , CD7CD7--, CD4/CD8, CD4/CD8vv, , CD25CD25++, CD30, CD30vv, cytotoxic markers, cytotoxic markers--
frequent expression of frequent expression of CCR4CCR4 and and FoxP3FoxP3 (regulatory T(regulatory T--cells)cells)TCR clonal rearrangement; HTLVTCR clonal rearrangement; HTLV--1 monoclonal1 monoclonal
FoxP3FoxP3
![Page 66: International PTCL Study - Benvenuto su AMS Campus ...campus.unibo.it/85279/68/Pileri_PTCL_3.pdf · International PTCL Study ... Supervised analysis 155 genes: 91 down-regulated and](https://reader030.fdocuments.in/reader030/viewer/2022012909/5b5673ed7f8b9ac5358cd78b/html5/thumbnails/66.jpg)